Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Open Access Highly Accessed Research article

Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate

Sang-Won Lee12, Hee-Jin Park12, Beom Kyung Kim145, Kwang-Hyub Han1345, Soo-Kon Lee123, Seung Up Kim145* and Yong-Beom Park123*

Author Affiliations

1 Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu Seoul, 120-752, Korea

2 Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine,; 50 Yonsei-ro, Seodaemun-gu; Seoul, 120-752, Korea

3 Department of Medical Sciences, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu; Seoul, 120-752, Korea

4 Institute of Gastroenterology, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu; Seoul, 120-752, Korea

5 Liver Cirrhosis Clinical Research Center, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu; Seoul, 120-752, Korea

For all author emails, please log on.

Arthritis Research & Therapy 2012, 14:R232  doi:10.1186/ar4075

Published: 29 October 2012

Additional files

Additional file 1:

The definition of the cumulative dose of each medication. Figure showing the cumulative dose of each medication, which was defined as the accumulated area under the curve (AUC) from the time of drug initiation to the time of liver stiffness measurement (LSM) during interval follow-up days.

Format: TIFF Size: 98KB Download file

Open Data

Additional file 2:

Correlation between liver stiffness measurement (LSM) values and other variables. Table showing gamma-GT levels and the cumulative doses of leflunomide and prednisolone significantly correlated with LSM; the cumulative dose of methotrexate showed no significant correlation with LSM.

Format: PDF Size: 42KB Download file

This file can be viewed with: Adobe Acrobat Reader

Open Data